SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors debate the impact of short-term volatility and distribution challenges against the company's long-term growth potential and market share expansion. The community is actively discussing potential acquisition rumors, the performance of the Alani Nu brand, and whether recent price fluctuations represent a generational buying opportunity or further downside risk.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending due to its recent partnership with the U.S. Army to develop rare earth processing facilities on military bases, a move community members view as a vital step toward U.S. supply chain independence. While some investors see the stock as a critical infrastructure play and are accumulating on dips, others are vocalizing concerns regarding high volatility, potential dilution from recent financing, and skepticism about the company's long-term commercialization timeline.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as the community closely monitors trial updates, including EMA approval for commercial GP2 peptide use and ongoing discussions regarding interim trial analysis protocols. Investors remain focused on the potential for institutional movement and strategic partnerships, as high short-interest dynamics continue to drive significant volatility in the stock.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc is trending as investors debate the potential for a regulatory turnaround following the resignation of the FDA chief and speculation surrounding the company's prospects for a third BLA resubmission. The community is sharply divided, with some traders betting on a high-risk squeeze driven by institutional activity and political shifts, while others emphasize the firm's liquidity constraints, previous regulatory setbacks, and significant staffing reductions.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is currently sparking intense debate within the crypto community, with some investors betting on a potential meme coin recovery tied to broader Solana ecosystem momentum, while critics cite recent treasury exploit concerns and ongoing price volatility as signs of a deeper decline.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is facing intense volatility and heavy margin liquidation, leading the community to intensely debate whether the stock is hitting a generational bottom or trapped in a sustained downward spiral. Investors are closely monitoring its structural support levels amid broad semiconductor weakness, while traders remain sharply divided on whether recent intraday rebounds are legitimate reversal signals or merely bear traps.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending as investors aggressively build positions in anticipation of a potential lithium market supercycle, driven by increasing demand for energy storage and expectations of an earnings beat. The stock has seen massive institutional accumulation and significant price appreciation, with community sentiment shifting from caution to bullish momentum as analysts upgrade targets and lithium futures show sustained strength.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the community anticipates a decision on the FDA's PDUFA date for the use of Auvelity in treating Alzheimer's disease agitation. Investors are keenly focused on upcoming pipeline developments and potential sales acceleration, while ongoing discussions highlight the strategic value of the company's CNS portfolio and its path toward profitability.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending following a significant surge in trading volume and share price, with the community actively discussing potential institutional accumulation and the stock's reclaim of the critical $5 price level. Investors remain focused on upcoming earnings and the company's long-term oncology pipeline, debating whether this momentum marks a sustained breakout or a temporary reaction to market activity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing intense market volatility as investors weigh the upcoming July 29 FDA advisory committee meeting for Deramiocel against a recent patent infringement lawsuit filed by Mesoblast. While the community is actively debating the potential impact of the legal dispute and concerns regarding the statistical analysis plan, bulls remain focused on the potential for a positive adcom vote and the underlying clinical data for DMD treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VirnetX Announces New Infrastructure Intelligence Platform, iSCOUT

VirnetX Holding Corporation (Nasdaq: VHC), a global leader in secure communications and zero-trust cybersecurity solutions, today announced iSCOUT (Intelligent Situational Command, Orchestration & Unified Telemetry), a new platform designed to give organizations a single, real-time situational...

Virnetx (NASDAQ:VHC) Shares Down 4.7% - Here's Why

Virnetx (NASDAQ:VHC) Shares Down 4.7% - Should You Sell...

Virnetx (NASDAQ:VHC) Stock Price Up 2.8% - Time to Buy?

Virnetx (NASDAQ:VHC) Stock Price Up 2.8% - Here's What Happened...

Virnetx (NASDAQ:VHC)  Shares Down 1.9%   - Should You Sell?

Virnetx (NASDAQ:VHC) Stock Price Down 1.9% - Here's What Happened...

Virnetx (NASDAQ:VHC) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Virnetx from a "hold" rating to a "sell" rating in a research report on Saturday...

VirnetX (NYSE:VHC) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

VirnetX (NYSE:VHC) Share Price Passes Above 200-Day Moving Average - What's Next...

VirnetX (NYSE:VHC) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

VirnetX (NYSE:VHC) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened...

VirnetX (NYSE:VHC) Shares Cross Above 200 Day Moving Average - Here's What Happened

VirnetX (NYSE:VHC) Stock Crosses Above 200 Day Moving Average - Should You Sell...

VirnetX (NYSE:VHC) Shares Cross Above 200 Day Moving Average - Should You Sell?

VirnetX (NYSE:VHC) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell...

VirnetX (NYSE:VHC) Shares Pass Above 200 Day Moving Average - Should You Sell?

VirnetX (NYSE:VHC) Shares Cross Above 200 Day Moving Average - Time to Sell...

VirnetX Holding Corp. engages in the provision of Internet security software and technology solutions to facilitate secure network communications, including 5G and 4G LTE. Its products include War Room, Gabriel secure gateway, collaboration suite, secure domains, secure communication platform, and connection technology. The company was founded on August 5, 2005 and is headquartered in Zephyr Cove, NV.

Virnetx Holding Corp

VirnetX Stock Soars To 30-Month High Today: What’s Driving The Rally?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

VHCVirnetx Holding Corp

Fundamentals

Latest VHC News